Working Group

Clinical Trials

Connecting global clinical trial networks and funders to improve coordination of clinical trial responses to epidemics and pandemics

  • Funder co-chair: Yazdan Yazdanpanah, Director, INSERM-ANRS Emerging Infectious Diseases Agency, France
  • Clinical Trial Networks co-chair: John Amuasi, ALERRT, KNUST Department of Global Health, Ghana
  • Secretariat co-chair:  Alice Norton, Head of GloPID-R Research & Policy Team


Publications & reports

Foster et al.
How funders can support improved clinical trial practice for outbreaks
The Lancet, July 2023
Read the publication

Norton et al.
Preparing for a pandemic: highlighting themes for research funding and practice—perspectives from the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R)
BMC Medicine, 2020, 18:273
Read the publication

Sigfrid, L., Maskell, K., Bannister, P. G., Ismail, S. A., Collinson, S., Regmi, S., … & Carson, G. (2020)
Addressing challenges for clinical research responses to emerging epidemics and pandemics: a scoping review
BMC medicine, 18(1), 1-15.
Read the publication

Gobat N., Amuasi J., Yazdanpanah ., Sigfrid L., Davies H., Byrne, J-P., Carson G., Christopher Butler C., Nichol C., Goossens H.
Advancing preparedness for clinical research during infectious disease epidemics
ERJ Open Research 2019 5: 00227-2018; DOI: 10.1183/23120541.00227-2018
Read the publication

Sigfrid L., Maskell K., Gobat N., et al.
Reaching out: a meeting to advance clinical research preparedness for infectious disease outbreaks. 2018
Read the publication

Aims & objectives

The Clinical Trials Working Group aims to bring global funders and clinical trial networks together to explore how funders may facilitate and enable the coordination of timely, well-designed, effective clinical trial responses to future epidemics and pandemics. We wish to facilitate timely data sharing, and generate evidence to inform health responses, improve outcomes and control outbreaks.


The COVID-19 pandemic has produced examples of successful trials generating data during the pandemic, in time to inform clinical practice and improve survival rates. Diagnostic tests were developed within weeks, therapeutics (dexamethasone) in 138 days, and vaccines in just over 300 days after the WHO declared a public health emergency of international concern. However, the ongoing pandemic has also highlighted remaining and new challenges to effective research responses, including the proliferation of trials that compete for inclusion of participants and are underpowered to meet their stated aims.

This working group was originally convened early 2017 following the GloPID-R response to the Zika epidemic. Its goal was to gather clinical trial networks funded by GloPID-R members in order to share experiences and good practices and to identify and address challenges to clinical research responses to new and re-emerging outbreaks. Following experiences during the recent pandemic, we have revitalized the group and expanded the membership to create a globally representative working group. One of our key initial priorities is to identify and agree upon standards for funders, which will facilitate coordination of global clinical trial responses to future outbreaks of public health significance.

Participating organizations


  • Japan Agency for Medical Research and Development (AMED)
  • French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
  • The Federal Ministry of Education and Research (BMBF)
  • Bill & Melinda Gates Foundation
  • Canadian Institute of Health Research (CIHR)
  • European Commission (EC)
  • European and Developing Countries Clinical Trials Partnership (EDCTP 3)
  • São Paulo Research Foundation (FAPESP)
  • National Institutes of Health (NIH)
  • Pasteur Network
  • South African Medical Research Council (SA MRC)
  • UK Department of Health and Social Care (UK DHSC)
  • UK Research and Innovation Medical Research Council (UKRI MRC)
  • Wellcome Trust

Clinical Trial Networks (CTNs)

  • The African coalition for Epidemic Research, Response and Training (ALERRT)
  • Brazilian Research in Intensive Care Network (BRICnet)
  • Canadian COVID-19 Network of Clinical Trials Networks
  • Canadian Immunization Research Network (CIRN)
  • COVID-19 Clinical Research Coalition (crc19)
  • Department of International Trials, Center for Clinical Sciences – National Center for Global Health and Medicine (DTI/ARISE)
  • European Network for COVID-19 Therapeutic Trials: DisCoVeRy, ECRAID-PRIME, EU- SolidAct & REMAP-CAP
  • European Clinical Research Alliance on Infectious Diseases (ECRAID)
  • International Severe Acute Respiratory and emerging Infection Consortium (ISARIC)
  • Indonesia Research Partnership on Infectious Diseases (INA-RESPOND)
  • Oxford University Clinical Research Unit (OUCRU)
  • Oxford University Clinical Research Unit – Nepal (OUCRU-NP)
  • The Pan-African Network for Rapid Research, Response, Relief and Preparedness for Infectious Disease Epidemics (PANDORA-ID-NET)
  • Randomised Evaluation of COVID-19 Therapy (RECOVERY)
  • The Global Health Network (REDe / TGHN)
  • South East Asian Research & education in Critical care Health /Pakistan Registry of Intensive Care (SEARCH/PRICE)
  • European Network for COVID-19 Trials for Vaccines (VACCELERATE)


  • Coalition for Epidemic Preparedness Innovations (CEPI)
  • GloPID-R Data Sharing Working Group
  • World Health Organization (WHO)

EU Flag

The GloPID-R Secretariat is a project which receives funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101094188.